Beyond amplification: precision approaches to targeting HER2.

Area of Science:

• Oncology
• Genetics
• Pharmacology

Background:

• Metastatic breast cancer (MBC) with activating HER2 mutations presents a therapeutic challenge.
• HER2-targeted therapies, including tyrosine kinase inhibitors (TKIs) combined with trastuzumab, are emerging as a treatment strategy.
• Understanding the molecular landscape of response and resistance is crucial for optimizing treatment outcomes.

Purpose of the Study:

• To investigate the efficacy of HER2-directed tyrosine kinase inhibitor combinations with trastuzumab in metastatic breast cancer patients with HER2 mutations.
• To explore the molecular mechanisms of response and acquired resistance through correlative genomic analyses.
• To identify patterns of molecular evolution during treatment to inform future therapeutic strategies.

Main Methods:

• Retrospective analysis of patients with HER2-mutant metastatic breast cancer treated with HER2-directed TKI and trastuzumab combinations.
• Correlative genomic profiling of tumor samples obtained at baseline and during treatment.
• Analysis of on-target and downstream molecular alterations to identify response patterns and resistance mechanisms.

Main Results:

• HER2-directed TKI and trastuzumab combinations demonstrated activity in both hormone receptor-negative and -positive HER2-mutant metastatic breast cancer.
• Correlative genomics identified significant on-target and downstream molecular evolution throughout treatment.
• Specific molecular alterations were associated with treatment response and the development of acquired resistance.

Conclusions:

• Combination therapy with HER2-directed TKIs and trastuzumab is a viable strategy for HER2-mutant metastatic breast cancer.
• Understanding treatment-induced molecular evolution is key to predicting response and overcoming resistance.
• Further refinement of precision therapies targeting HER2 mutations in breast cancer is warranted.